Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares US Real Estate ETF
IYR
|
+$1.48B |
| 2 |
Apple
AAPL
|
+$610M |
| 3 |
Amazon
AMZN
|
+$538M |
| 4 |
NUAN
Nuance Communications, Inc.
NUAN
|
+$379M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$337M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.14B |
| 2 |
VAR
Varian Medical Systems, Inc.
VAR
|
+$466M |
| 3 |
State Street Consumer Staples Select Sector SPDR ETF
XLP
|
+$420M |
| 4 |
Tesla
TSLA
|
+$251M |
| 5 |
IPHI
INPHI CORPORATION
IPHI
|
+$242M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.39% |
| 2 | Financials | 7.95% |
| 3 | Communication Services | 5.87% |
| 4 | Consumer Discretionary | 5.85% |
| 5 | Healthcare | 5.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3326
Anavex Life Sciences
AVXL
$292M
| $292K | ﹤0.01% |
12,768
-74,003
| -85% | -$1.1M |
|
3327
Douglas Dynamics
PLOW
$1.05B
| $292K | ﹤0.01% |
7,178
-16,987
| -70% | -$746K |
|
|
CVA
3328
DELISTED
Covanta Holding Corporation
CVA
| $292K | ﹤0.01% |
16,615
-97,127
| -85% | -$1.48M |
|
|
CRON
3329
Cronos Group
CRON
$1.05B
| $291K | ﹤0.01% |
33,865
-41,780
| -55% | -$346K |
|
|
TEF
3330
DELISTED
Telefonica
TEF
| $291K | ﹤0.01% |
66,406
-71,197
| -52% | -$308K |
|
3331
Fidelity MSCI Communication Services Index ETF
FCOM
$1.82B
| $290K | ﹤0.01% |
5,324
+2,488
| +88% | +$130K |
|
|
IGD
3332
Voya Global Equity Dividend and Premium Opportunity Fund
IGD
$513M
| $290K | ﹤0.01% |
44,941
-29,084
| -39% | -$172K |
|
|
JNCE
3333
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $290K | ﹤0.01% |
42,538
+19,196
| +82% | +$159K |
|
3334
Arlo Technologies
ARLO
$1.7B
| $289K | ﹤0.01% |
42,779
-85,494
| -67% | -$557K |
|
3335
CALL
CF Industries
CF
$18.1B
| $288K | ﹤0.01% |
5,600
-2,600
| -32% | -$132K |
|
3336
Dolby
DLB
$5.67B
| $288K | ﹤0.01% |
2,926
-6,836
| -70% | -$675K |
|
3337
Entravision Communication
EVC
$1.03B
| $288K | ﹤0.01% |
43,142
-23,309
| -35% | -$105K |
|
3338
CALL
Texas Instruments
TXN
$255B
| $288K | ﹤0.01% |
1,500
| – | – |
|
|
BFX
3339
DELISTED
BowFlex Inc.
BFX
| $288K | ﹤0.01% |
17,037
-22,302
| -57% | -$376K |
|
|
ATNX
3340
DELISTED
Athenex, Inc. Common Stock
ATNX
| $287K | ﹤0.01% |
3,107
-2,415
| -44% | -$220K |
|
3341
Omeros
OMER
$908M
| $286K | ﹤0.01% |
19,291
-39,276
| -67% | -$659K |
|
|
PR
3342
Permian Resources
PR
$17.4B
| $286K | ﹤0.01% |
42,181
-271,794
| -87% | -$1.4M |
|
3343
Goosehead Insurance
GSHD
$2.32B
| $285K | ﹤0.01% |
2,242
-10,220
| -82% | -$1.04M |
|
3344
Q32 Bio
QTTB
$453M
| $285K | ﹤0.01% |
2,180
+471
| +28% | +$58.8K |
|
|
VBIV
3345
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $285K | ﹤0.01% |
2,839
-2,251
| -44% | -$219K |
|
|
ACH
3346
DELISTED
Alum Corp of China Ltd
ACH
| $285K | ﹤0.01% |
19,236
-12,264
| -39% | -$166K |
|
3347
Amplify Blockchain Technology ETF
BLOK
$1.11B
| $284K | ﹤0.01% |
+5,945
| New | +$291K |
|
|
OBSV
3348
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $284K | ﹤0.01% |
93,973
-5,259
| -5% | -$15.5K |
|
|
AERI
3349
DELISTED
Aerie Pharmaceuticals
AERI
| $284K | ﹤0.01% |
17,737
-29,998
| -63% | -$515K |
|
3350
Crinetics Pharmaceuticals
CRNX
$8.91B
| $283K | ﹤0.01% |
15,061
-9,521
| -39% | -$167K |
|
Similar funds
Barclays's Q2 2021 Portfolio in Review
As of Q2 2021, Barclays held 5,234 positions worth $212B, up 14% from $186B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Barclays deployed $11.1B of net new capital in Q2 2021, opening 558 new positions and adding to 1,559 existing holdings. Its largest new stake was Proofpoint, Inc.: 1,241,690 shares worth $216M.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 13% a quarter earlier, followed by Financials and Communication Services.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $1.14B trimmed.
- Barclays's largest Q2 2021 buy was Proofpoint, Inc.: 1,241,690 shares worth $216M.
- Barclays added most to iShares US Real Estate ETF in Q2 2021, an estimated $1.48B increase.
- Barclays's biggest Q2 2021 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.14B.
- Barclays fully exited Varian Medical Systems, Inc. in Q2 2021, selling an estimated $466M.
- Barclays's ten largest holdings make up 36% of its $212B portfolio in Q2 2021.
- Barclays opened 558 new positions and closed 327 in Q2 2021.
- Barclays's portfolio value rose 14% quarter-over-quarter to $212B.
Based on Barclays's 13F filing for Q2 2021, filed 13 Aug 2021.